Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hodgkin Disease 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Rituximab 33Cyclophosphamide 23Filgrastim 18Peripheral Blood Stem Cell Transplantation 16Etoposide 13fludarabine phosphate 12Vincristine 12Prednisone 11Bortezomib 11sargramostim 10Radiotherapy 10Doxorubicin 8Cytarabine 8Cyclosporine 8Vorinostat 7Lenalidomide 7Cisplatin 7Biopsy 7tanespimycin 6Melphalan 6Magnetic Resonance Spectroscopy 6Ifosfamide 6bryostatin 1 5alvocidib 5aldesleukin 5Specimen Handling 5Methylprednisolone 5Methotrexate 5Interferon-alpha 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Follicular × indolepropanol phosphate × Clear all
NCT00086944 2013-01-24

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡